Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Официальное название

Prospective, Multicenter, Randomized, Double-blind, Parallel Group, Placebo- Controlled, Efficacy and Safety Phase 3 Study of an Intravenous Human Plasma- Derived C1 Esterase Inhibitor (C1-INH) Concentrate in Participants With Congenital C1-INH Deficiency for the Treatment and Pre-procedure Prevention of Acute Hereditary Angioedema Attacks

Обзор

Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks

Вмешательства

• Препарат OCTA-C1-INH
  OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
• Другое Placebo
  0.1 mL/kg BW 0.9% sodium chloride injection

Первичные конечные точки

• Time (h) to beginning of unequivocal symptom relief at the defining site in blinded participants. [Срок оценки: Within 4 hours after injection]

Вторичные конечные точки (3)

• Percentage of participants responding to treatment [Срок оценки: within 4 hours after injection]
• Time to beginning of unequivocal symptom relief at all sites involved [Срок оценки: Within 4 hours after injection]
• Changes in symptom severity at the defining site by VAS severity rating [Срок оценки: Within 4 hours after injection]

Критерии участия

Критерии включения

• Is at least 18 years of age (applicable for 1st study phase) or is at least 2 years of age (applicable for 2nd study phase)
• Has confirmed diagnosis of HAE type I or II
• Has had at least 3 moderate or severe HAE attacks (excluding extremity attacks) in the last 3 months before the Screening Visit. For participants ≥2 and ≤12 years of age, has had at least 1 moderate or severe HAE attack (excluding extremity attacks) in the last 6 months before Screening Visit
• Has a documented congenital C1-INH functional activity <50% with or without C1-INH deficiency and C4 antigen level below the laboratory reference range
• Participant or the participant's legally authorized representative(s) has signed informed consent (as required by local law), with the assent of participants legally capable of providing it, as applicable
• States willingness to comply with all study procedures and availability for the duration of the study
• If the participant is of childbearing potential (CBP), has a negative pregnancy test and must have been using a highly effective method of contraception and continue to do so until at least 2 weeks after their last dose (for both blinded and open-label doses of IMP). Not of CBP is defined as surgically sterilized (hysterectomy, bilateral oophorectomy) or who are postmenopausal (defined as women with no menses for 12 months without an alternative medical cause). Highly effective methods of contraception:

• Combined hormonal contraception (estrogens and progesterone) methods such as oral, implantable, intravaginal, injectable, or transdermal contraceptives at a stable dose for a minimum of 1 full cycle (hormonal contraceptives must inhibit ovulation) and for at least 4 weeks before screening
• Progesterone only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
• Intrauterine device
• Intrauterine hormone-releasing system inserted at least 4 weeks before screening
• Bilateral tubal ligation/occlusion or vasectomized partner (with surgical success confirmed by medical assessment) OR Agrees to abstain from heterosexual intercourse during study participation and to use a highly effective contraceptive (as described above) as backup if they become sexually active during the study. Abstinence is only acceptable if this is the participant's usual lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception
• Note: If a participant of CBP has a positive or suspected positive urine pregnancy test within 72 hours prior to treatment, a serum pregnancy test will be required
• Male participants must not plan to father a child or donate sperm for 90 days after their last dose of study drug (for both blinded and open-label doses of the IMP). However, there are no official contraception requirements for male participants during the study.

Inclusion Criteria for IMP Dosing for QAT:

• Has confirmed QAT per definition criteria
• Has a swelling episode that is new and not the continuation of a previous HAE attack

Критерии исключения

• Has a history of clinically relevant antibody development against C1-INH
• Has a medical history consistent with Type 3 HAE (i.e., onset at age above 40 year, no family history, no known HAE mutation, low C1q level in plasma)
• Has a history of allergic reaction to C1-INH or other blood/plasma product
• Has a history of B-cell malignancy that was unresolved in the past 5 years
• Has a narcotic and/or alcoholic addiction
• Has participated in any other investigational drug evaluation within 30 days before screening
• Is pregnant or breastfeeding
• Has any clinically significant medical or psychiatric condition that, in the investigator's opinion would interfere with the participant's ability to participate in the study
• Has a history of thromboembolic events (TEEs), myocardial infarction, unstable angina pectoris, critical aortic stenosis, cerebrovascular accident, transient ischemic attack, severe peripheral vascular disease, or disseminated intravascular coagulation within one year before screening
• (applicable until IDMC review of the interim preliminary safety and efficacy data): has clinically significant derangement in measurements of cardiovascular status (i.e. uncontrolled arterial hypertension, cardiac insufficiency New York Heart Association (NYHA) class III-IV), pulmonary status (i.e., COPD GOLD classification 3 and 4, severe asthma) and renal status (i.e., eGFR below 90 ml/min per 1.73 m2)

Exclusion Criteria for IMP Dosing for QAT:

• Has received blood or a blood product for prophylactic or acute treatment with any C1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykinin and kallikrein pathway inhibitors (e.g., ecallantide, icatibant, berotralstat), or treatment with tranexamic acid within 14 days before dosing with the IMP (or is not willing to abstain from these medications throughout the study)
• started or changed hormone replacement therapy or selective estrogen receptor modulators (e.g., tamoxifen) within 14 days before IMP dosing
• Started or changed androgen therapy (e.g. testosterone, dehydro- epiandrosterone/androstenedione, oxandrolone, danazol, stanozolol) within 14 days before IMP dosing or is not willing to maintain a stable dose throughout the study
• Started or changed the dose of monoclonal antibodies e.g. lanadelumab within 11 weeks before dosing or not willing to maintain a stable dose throughout the study
• Has used narcotic pain medications or non-opioid analgesics within 7 days before IMP dosing for a QAT
• Has received OCTA-C1-INH within 14 days before IMP dosing

Exclusion Criteria for IMP Dosing for PK:

• Has received blood or a blood product for prophylactic or acute treatment with any C1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykinin and kallikrein pathway inhibitors (e.g., ecallantide, icatibant, berotralstat), or treatment with tranexamic acid within 14 days before dosing with the IMP (or is not willing to abstain from these medications throughout the study)
• Is receiving hormone replacement therapy or selective estrogen receptor modulators (e.g., tamoxifen) and has had their dose changed within 14 days before IMP dosing
• Is receiving or has received androgen therapy (e.g., testosterone, dehydroepiandrosterone/androstenedione, oxandrolone, danazol, stanozolol) IN ANY DOSE within 14 days before dosing
• Started or changed the dose of monoclonal antibodies e.g lanadelumab within 11 weeks before dosing or not willing to maintain a stable dose throughout the study
• Has used narcotic pain medications or non-opioid analgesics within 7 days before IMP dosing
• Has received IMP within 14 days before IMP dosing
• Has planned dental, medical, or surgical procedures during the PK Period that will require pre-procedural prevention

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Двойное слепое

Основная цель

Лечение

Центры проведения

Turkey (Türkiye) · 4 центра

• Octapharma Research Site — Ankara
• Octapharma Research Site — Istanbul
• Octapharma Research Site — Izmir
• Octapharma Research Site — Sakarya

США · 3 центра

• Octapharma Research Site — Centennial
• Octapharma Research Site — Farmington Hills
• Octapharma Research Site — Toledo

Украина · 3 центра

• Octapharma Research Site — Kyiv
• Octapharma Research Site — Lviv
• Octapharma Research Site — Lviv

Индия · 2 центра

• Octapharma Research Site — Bangalore
• Octapharma Research Site — Patna

Мексика · 2 центра

• Octapharma Research Site — Mexico City
• Octapharma Research Site — México

Перу · 2 центра

• Octapharma Research Site 5102 — Lima
• Octapharma Research Site 5103 — Lima

Albania · 1 центр

• Octapharma Research Site — Tirana

Аргентина · 1 центр

• Octapharma Research Site — Rosario

Армения · 1 центр

• Octapharma Research Site — Yerevan

Болгария · 1 центр

• Octapharma Research Site — Sofia

Montenegro · 1 центр

• Octapharma Research Site — Podgorica

Румыния · 1 центр

• Octapharma Research Site — Cluj-Napoca

Сербия · 1 центр

• Octapharma Research Site — Kragujevac

Идентификаторы

NCT: NCT06361537 · CONE-02

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗